Reliant Technologies
This article was originally published in The Gray Sheet
Executive Summary
Mountain View, Calif., aesthetics device maker announces 510(k) clearance July 2 of its Fraxel re:pair laser with Fractional Deep Dermal Ablation for ablation, coagulation and skin resurfacing based on data from an ongoing, 200-patient, 10-site clinical trial. In the first phase of the trial, over 75% of patients treated with Fraxel re:pair showed improved appearance of rhytids, vascular dyschromia, pigmentation and skin laxity. Two later phases are evaluating the device for scar treatment. Reliant's other lasers on the market include Fraxel re:store for skin resurfacing and scar and wrinkle treatment, and Fraxel re:fine for gentle skin rejuvenation...
You may also be interested in...
Reliant Technologies IPO Will Support 2008 Launch Of Skin Repair Laser
Aesthetic laser manufacturer Reliant Technologies will launch its Fraxel Re:pair system for treatment of severe skin conditions in the first quarter of 2008, supported by the proceeds of a proposed initial public stock offering of up to $95 million
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.